[HTML][HTML] Symptomatic and disease-modifying therapy pipeline for Alzheimer's disease: Towards a personalized polypharmacology patient-centered approach

X Morató, V Pytel, S Jofresa, A Ruiz… - International Journal of …, 2022 - mdpi.com
Since 1906, when Dr. Alois Alzheimer first described in a patient “a peculiar severe disease
process of the cerebral cortex”, people suffering from this pathology have been waiting for a …

[HTML][HTML] Advanced extracellular vesicle bioinformatic nanomaterials: from enrichment, decoding to clinical diagnostics

Y Zhang, L Zhao, Y Li, S Wan, Z Yuan, G Zu… - Journal of …, 2023 - Springer
Extracellular vesicles (EVs) are membrane nanoarchitectures generated by cells that carry a
variety of biomolecules, including DNA, RNA, proteins and metabolites. These …

[HTML][HTML] Shared genetic architecture between the two neurodegenerative diseases: Alzheimer's disease and glaucoma

C Zheng, S Liu, X Zhang, Y Hu, X Shang… - Frontiers in aging …, 2022 - frontiersin.org
Background: Considered the representatives of neurodegenerative diseases, Alzheimer's
disease and glaucoma are complicated progressive neuropathies affected by both genetic …

[HTML][HTML] Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer's Disease in Rats

MA Abd Elmaaboud, RS Estfanous, A Atef, AM Kabel… - Pharmaceuticals, 2023 - mdpi.com
Alzheimer's disease (AD) is the most common form of neurodegenerative disorders
worldwide. Its pathologic features include massive neuroinflammation with abnormal …

[HTML][HTML] Galantamine-memantine hybrids for Alzheimer's disease: The influence of linker rigidity in biological activity and pharmacokinetic properties

F Basagni, JA Ortega, SM Bertozzi, A Armirotti… - European Journal of …, 2023 - Elsevier
Neurodegenerative processes characterizing Alzheimer's disease (AD) are strictly related to
the impairment of cholinergic and glutamatergic neurotransmitter systems which provoke …

Fibroblast growth factor 10 ameliorates neurodegeneration in mouse and cellular models of Alzheimer's disease via reducing tau hyperphosphorylation and neuronal …

K Guo, W Huang, K Chen, P Huang, W Peng, R Shi… - Aging …, 2023 - Wiley Online Library
Alzheimer's disease (AD) is characterized with senile plaques formed by Aβ deposition, and
neurofibrillary tangles composed of hyperphosphorylated tau protein, which ultimately lead …

Patient‐related benefits of amyloid PET imaging in dementia: Rationale and design of the German randomized coverage with evidence development study ENABLE

SJ Teipel, A Spottke, H Boecker… - … Research & Clinical …, 2023 - Wiley Online Library
The utility of amyloid positron emission tomography (PET) for the etiological diagnosis of
dementia and its impact on functional status of patients in routine care are currently unclear …

[HTML][HTML] Cognitive Trajectories in Preclinical and Prodromal Alzheimer's Disease Related to Amyloid Status and Brain Atrophy: A Bayesian Approach

SJ Teipel, M Dyrba, F Levin… - Journal of …, 2023 - content.iospress.com
Background: Cognitive decline is a key outcome of clinical studies in Alzheimer's disease
(AD). Objective: To determine effects of global amyloid load as well as hippocampus and …

La efectividad del ejercicio aeróbico según la dosis para reducir los trastornos cognitivos en la enfermedad de Alzheimer: un protocolo de investigación

S Marie - 2023 - repositorio.usj.es
Introducción: La enfermedad de Alzheimer es la enfermedad neurodegenerativa la más
común y su incidencia está aumentado. Los fármacos son el principal recurso para …

[PDF][PDF] Professur für Allgemeine und Biopsychologie

EB von Saskia Kriegel - tu-chemnitz.de
Alter verschlechtert sich die glymphatische Aktivität, wodurch sich signifikante Mengen an
Proteinaggregationen ablagern und sich das Risiko für neurodegenerative Erkrankungen …